课题基金 / 基金详情

Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Atrial Fibrillation (COBRRA AF)

Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Atrial Fibrillation (COBRRA AF)
利伐沙班和阿哌沙班治疗房颤 (COBRRA AF) 出血风险的比较
批准号：
432966
负责人：
Castellucci Lana
金额：
$7.29万
依托单位：
Ottawa Hospital Research Institute
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-04-01 至 2021-04-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=432966&lang=en
关键词：
Atrial Fibrillation, Bleeding, Anticoagulation

项目摘要

项目成果

Castellucci Lana的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The direct oral anticoagulants (DOACs) apixaban and rivaroxaban have been compared to standard therapy for stroke prevention in atrial fibrillation (SPAF) in randomized controlled trials (RCT) and are both approved by Health Canada. No safety or efficacy
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COBRRA trial: Comparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism
  • 批准号：
    478040
  • 项目类别：
    Operating Grants
  • 资助金额：
    $46.26万
  • 财政年份：
    2023
  • 负责人：
    Castellucci Lana
  • 依托单位：
    Ottawa Hospital Research Institute
Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Atrial Fibrillation (COBRRA AF)
  • 批准号：
    450705
  • 项目类别：
    Operating Grants
  • 资助金额：
    $161.06万
  • 财政年份：
    2021
  • 负责人：
    Castellucci Lana
  • 依托单位：
    Ottawa Hospital Research Institute
Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial